Blood-based biomarkers are set to make biological assessment of Alzheimer's disease much quicker and more accessible than has been possible with imaging and CSF biomarkers. Does this mean the disease can now be defined as a purely biological entity?
Dr. Nicolas Villain outlines why it is still so important to consider both clinical symptoms and biological findings when making a diagnosis.
« Previous episode: Episode 13: Advances in MASLD and MASH
Further reading
Dubois B, Villain N, Schneider L, et al. Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation. JAMA Neurol 2024; 81: 1304–1311.
Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's Dement 2024; 20: 5143–5169.
